Predictive Role of Activated Leukocyte Cell Adhesion Molecule in Colon Cancer

Hamit Karayagiz1 , Umit Sekmen2* and Melih Paksoy2

1 Department of General Surgery, Acibadem Aile Hospital, Turkey 2 Department of General Surgery, Acibadem Fulya Hospital, Turkey

^*Correspondance to: Umit Sekmen 

 PDF  Full Text DOI: 10.25107/2474-1647.3200

Abstract

Aim: Colon cancer is one of the most common and deadly cancers worldwide. Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been found to be associated with various malignancies. We investigated the expression of ALCAM in colon cancer patients, as well as its association with tumor size. Materials and Methods: A total of 90 people, 50 patients with stage II colon cancer and 40 healthy controls were included in the study. Serum ALCAM and Carcinoembryonic Antigen (CEA) levels were measured in both groups. Tumor size was evaluated in the patient group. Results: Circulating ALCAM levels were higher in patients with colon cancer than in the control group. Serum ALCAM levels were especially elevated in patients with larger tumor size. Conclusion: ALCAM is overexpressed in colon cancer, and these results suggest that serum ALCAM levels may have a predictive role in the prognosis of this disease.

Keywords

Activated leucocyte cell adhesion molecule; ALCAM; CD166; Colon cancer; Prognosis

Cite the article

Karayagiz H, Sekmen U, Paksoy M. Predictive Role of Activated Leukocyte Cell Adhesion Molecule in Colon Cancer. Clin Surg. 2021; 6: 3200..